Both authors contributed equally to this work.
Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma
Article first published online: 1 JUN 2012
© 2012 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 25, Issue 4, pages 506–513, July 2012
How to Cite
Verma, D., Bivik, C., Farahani, E., Synnerstad, I., Fredrikson, M., Enerbäck, C., Rosdahl, I. and Söderkvist, P. (2012), Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell & Melanoma Research, 25: 506–513. doi: 10.1111/j.1755-148X.2012.01008.x
- Issue published online: 19 JUN 2012
- Article first published online: 1 JUN 2012
- Accepted manuscript online: 24 APR 2012 02:15AM EST
- PUBLICATION DATA Received 20 March 2012, received and accepted for publication 20 April 2012, published online 24 April 2012
Genetic variants of NLRP3 and NLRP1 are known to modulate levels of pro-inflammatory cytokine interleukin (IL)-1β. The purpose of this study was to investigate the association of NLRP3/NLRP1 polymorphisms with susceptibility and clinical features of malignant melanoma in a Swedish case–control study. Common variants in NLRP3/NLRP1 were investigated in sporadic malignant melanoma patients and healthy controls followed by analysis using logistic regression. NLRP3 variant (rs35829419) was significantly more common in male patients than in controls (OR, 2.22; CI, 1.27–3.86). Upon stratification, significant association with nodular melanoma was observed (OR, 2.89; CI, 1.33–6.30), which intensified in male patients (OR 4.03, CI 1.40–11.59). The NLRP1 variant (rs12150220) was significantly more common in fair-skinned female patients (OR, 1.85; CI, 1.04–3.33) and showed strong associations with nodular melanoma (OR, 6.03; CI, 1.33–25). Our data suggest that NLRP3/NLRP1 polymorphisms are associated with melanoma susceptibility; these findings warrant validation in other independent populations.